Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3082-3088

  Ganci, F ^a   Sacconi, A ^a   Bossel Ben Moshe, N ^b   Manciocco, V ^c   Sperduti, I ^d   Strigari, L ^e   Covello, R ^a   Benevolo, M ^a   Pescarmona, E ^a   Domany, E ^b   Muti, P ^f,g   Strano, S ^a,f   Spriano, G ^c   Fontemaggi, G ^a   Blandino, Giovanni ^a,f  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c Department of Otolaryngology ^*  (Italy)

^d Campus Bio Medico University   (Italy)

^e Laboratory of Medical Physics and Expert Systems   (Italy)

^f MCMASTER UNIVERSITY   (Canada)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical outcome; HNSCC; MicroRNA; TP53 mutation

Indexed keywords

MICRORNA; MICRORNA 139 3P; MICRORNA 151A 3P; MICRORNA 17 3P; MICRORNA 18B 5P; MICRORNA 19A 3P; MICRORNA 200A 3P; MICRORNA 205 5P; MICRORNA 21 3P; MICRORNA 21 5P; MICRORNA 324 5P; MICRORNA 331 3P; MICRORNA 429; MICRORNA 96 5P; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EXON; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; ONCOGENE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL RATE; TP53 GENE; UPREGULATION;

CLINICAL OUTCOME; HNSCC; MICRORNA; TP53 MUTATION;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84888787585     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt380     Document Type: Article

References (29)

1. Leemans CR, Braakhuis BJ, BrakenhoffRH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11: 9-22.
2. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993; 85: 95-111.
3. Balz V, Scheckenbach K, Gotte K et al. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003; 63: 1188-1191.
4. Hartmann A, Blaszyk H, McGovern RM et al. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 1995; 10: 681-688.
5. Di Agostino S, Strano S, Emiliozzi V et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10: 191-202.
6. Strano S, Dell'Orso S, Di Agostino S et al. Mutant p53: an oncogenic transcription factor. Oncogene 2007; 26: 2212-2219.
7. Fontemaggi G, Dell'Orso S, Muti P et al. Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle 2010; 9: 2464-2466.
8. Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 2005; 86: 347-363.
9. Poeta ML, Manola J, Goldwasser MA et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357: 2552-2561.
10. Erber R, Conradt C, Homann N et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 1998; 16: 1671-1679.
11. Peltonen JK, Vahakangas KH, Helppi HM et al. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study. Head Neck Oncol 2011; 3: 20.
12. Lindenbergh-van der Plas M, BrakenhoffRH, Kuik DJ et al. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2011; 17: 3733-3741.
13. Skinner HD, Sandulache VC, Ow TJ et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012; 18: 290-300.
14. Strano S, Dell'Orso S, Mongiovi AM et al. Mutant p53 proteins: between loss and gain of function. Head Neck 2007; 29: 488-496.
15. Ganci F, Sacconi A, Manciocco V et al. Molecular genetics and biology of head and neck squamous cell carcinoma: implications for diagnosis, prognosis and treatment. In Agulnik M, Head and Neck Cancer. InTech 2012; 73-122. Available from: http://www.intechopen.com/books/head-and-neck-cancer/pain-and-symptom-control-in-head-and-neck-cancer.
16. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714.
17. Babu JM, Prathibha R, Jijith VS et al. A miR-centric view of head and neck cancers. Biochim Biophys Acta 2011; 1816: 67-72.
18. Harris T, Jimenez L, Kawachi N et al. Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 2012; 180: 917-928.
19. Gee HE, Camps C, Buffa FM et al. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 2010; 116: 2148-2158.
20. Suzuki HI, Yamagata K, Sugimoto K et al. Modulation of microRNA processing by p53. Nature 2009; 460: 529-533.
21. Donzelli S, Fontemaggi G, Fazi F et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012; 19: 1038-1048.
22. Masciarelli S, Fontemaggi G, Di Agostino S et al. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene 2013; doi: 10.1038/onc.2013.106 [Epub ahead of print].
23. Enerly E, Steinfeld I, Kleivi K et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 2011; 6: e16915.
24. Thomas DG, Rabow L, Teasdale G. Serum myelin basic protein, clinical responsiveness, and outcome of severe head injury. Acta Neurochir Suppl (Wien) 1979; 28: 93-95.
25. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2: a001107.
26. Stransky N, EgloffAM, Tward AD et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-1160.
27. Nohata N, Hanazawa T, Kinoshita T et al. MicroRNAs function as tumor suppressors or oncogenes: aberrant expression of microRNAs in head and neck squamous cell carcinoma. Auris Nasus Larynx 2013; 40: 143-149.
28. Hui AB, Lin A, Xu W et al. Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin Cancer Res 2013; 19: 2154-2162.
29. Fu X, Han Y, Wu Y et al. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest 2011; 41: 1245-1253.